Trial Search Results

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD

A fellow eye controlled study of HUCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD. All subjects will be assigned to HUCNS-SC transplantation.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

StemCells, Inc.

Stanford Investigator(s):

Intervention(s):

  • Biological: HuCNS-SC sub-retinal transplantation

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - GA associated with AMD in both eyes. Total area of GA determined by fundus
   autofluorescence.

   - BCVA of 20/320 or better in each eye at screening assessment

Exclusion Criteria:

   - Prior or concurrent choroidal neovascularization in either eye by clinical exam and/or
   fluorescein angiography as determined by the investigator or the reading center.

   - Retinal or macular disease of any other cause in either eye.

   - Diagnosis of glaucoma in either eye.

   - Uncontrolled intraocular pressure in either eye

   - Compromised renal function defined as eGFR <60mL/min and urine protein-to-creatinine
   ration >0.3 is spot urine collection.

   - History of or active autoimmune disease.

   - Previous organ, tissue or bone marrow transplantation.

   - Seropositive for HIV, hepatitis B or C, or CMV IgM

Ages Eligible for Study

50 Years - 90 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting